Fletcher Sabine, Avery Vicky M
Discovery Biology, Eskitis Institute for Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia.
Malar J. 2014 Aug 31;13:343. doi: 10.1186/1475-2875-13-343.
Malaria is a devastating parasitic disease, causing more than 600,000 deaths annually. Drug resistance has rendered previous generation anti-malarials ineffective and is also rapidly emerging against the current therapeutics of choice, artemisinin and its derivatives, making the discovery of new anti-malarials with novel mechanisms of action a priority. The Coenzyme A (CoA) synthesis pathway, a well-known anti-microbial drug target that is also essential for the malaria parasite Plasmodium falciparum, has not yet been exploited in anti-malarial drug development. A novel high throughput approach for the identification of chemically diverse inhibitors of the CoA synthesis pathway is reported.
To identify novel CoA synthesis pathway inhibitors, a chemical rescue screening approach was developed. In short, a test compound was considered likely to inhibit the P. falciparum CoA synthesis pathway, if addition of the end product of the pathway, CoA, was able to negate the growth-inhibitory action of the compound on P. falciparum parasites.
The chemical rescue approach was employed to screen the Medicines for Malaria Venture malaria box and a small focussed compound library. This resulted in the identification of 12 chemically diverse potential inhibitors of the CoA pathway. To ascertain accurate potency and selectivity, the half-maximal inhibitory concentration (IC50 value) of these compounds was determined for both P. falciparum and a human cell line. Seven compounds showed submicromolar activity against the parasite, with selectivity indices ranging between six and greater than 300. CoA supplementation was confirmed to alleviate the effects on parasite growth and cell viability in a dose dependent manner. Microscopic investigation into the stage of effect and phenotype of treated parasites was performed on a selection of the active compounds.
The chemical rescue approach described resulted in the identification of a set of chemically diverse CoA synthesis pathway inhibitors with IC50 values ranging between 120 nM and 6 μM. The identified compounds will be utilized as tools for further investigating the parasite CoA synthesis pathway to define their exact mechanism of action. Furthermore, the chemical diversity of the compounds identified substantiates the suitability of this approach to identify novel starting points for future anti-malarial drug development.
疟疾是一种极具破坏力的寄生虫病,每年导致超过60万人死亡。耐药性已使上一代抗疟药物失效,并且针对当前的首选治疗药物青蒿素及其衍生物的耐药性也在迅速出现,因此发现具有新作用机制的新型抗疟药物成为当务之急。辅酶A(CoA)合成途径是一种著名的抗菌药物靶点,对恶性疟原虫也至关重要,但尚未在抗疟药物开发中得到利用。本文报道了一种用于鉴定CoA合成途径化学结构多样抑制剂的新型高通量方法。
为了鉴定新型CoA合成途径抑制剂,开发了一种化学拯救筛选方法。简而言之,如果添加该途径的终产物CoA能够消除化合物对恶性疟原虫的生长抑制作用,则认为测试化合物可能抑制恶性疟原虫的CoA合成途径。
采用化学拯救方法筛选了疟疾药物事业组织的疟疾药盒和一个小型聚焦化合物库。这导致鉴定出12种化学结构多样的CoA途径潜在抑制剂。为了确定准确的效力和选择性,测定了这些化合物对恶性疟原虫和人细胞系的半数最大抑制浓度(IC50值)。七种化合物对寄生虫表现出亚微摩尔活性,选择性指数在6到大于300之间。证实补充CoA以剂量依赖方式减轻对寄生虫生长和细胞活力的影响。对一系列活性化合物进行了显微镜检查,以研究处理后寄生虫的作用阶段和表型。
所描述的化学拯救方法导致鉴定出一组化学结构多样的CoA合成途径抑制剂,其IC50值在120 nM至6 μM之间。所鉴定的化合物将用作进一步研究寄生虫CoA合成途径以确定其确切作用机制的工具。此外,所鉴定化合物的化学多样性证实了该方法适用于确定未来抗疟药物开发的新起点。